Baird analyst Michael Ha raised the firm’s price target on Astrana Health to $67 from $54 and keeps an Outperform rating on the shares. The firm called the company a Top Pick and believes the company is grossly undervalued and on the precipice of unlocking a wealth of growth.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH: